{"id":191434,"date":"2024-06-18T22:22:49","date_gmt":"2024-06-19T03:22:49","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/06\/innovative-thinking-could-make-new-sickle-cell-treatments-more-accessible"},"modified":"2024-06-18T22:22:49","modified_gmt":"2024-06-19T03:22:49","slug":"innovative-thinking-could-make-new-sickle-cell-treatments-more-accessible","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/06\/innovative-thinking-could-make-new-sickle-cell-treatments-more-accessible","title":{"rendered":"Innovative Thinking Could Make New Sickle Cell Treatments More Accessible"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/innovative-thinking-could-make-new-sickle-cell-treatments-more-accessible2.jpg\"><\/a><\/p>\n<p>The cost of new gene-based sickle cell treatments isn\u2019t the only barrier to access. Coming up with new ways to treat the whole disease\u2014and person\u2014could make treatment more equitable.<\/p>\n<p>By <a class=\"\" href=\"https:\/\/www.scientificamerican.com\/author\/shobita-parthasarathy\/\">Shobita Parthasarathy<\/a><\/p>\n<p>Last fall, to great fanfare, US regulators approved <a href=\"https:\/\/www.scientificamerican.com\/article\/fda-approves-first-crispr-gene-editing-treatment-for-sickle-cell-disease\/\">two gene therapies for sickle cell disease<\/a>, and the European Union and UK soon followed. Many people hope that these treatments will provide a \u201c<a href=\"https:\/\/abcnews.go.com\/Health\/fda-approves-new-gene-therapies-sickle-cell-disease\/story?id=105482870\">functional cure<\/a>\u201d for the genetic condition, which causes rigid, misshapen red blood cells that lead to anemia, <a href=\"https:\/\/www.scientificamerican.com\/article\/people-with-sickle-cell-deserve-more-respect-from-health-care-providers\/\">episodes of extreme pain<\/a>, blood vessel and organ damage, stroke risk and lower life expectancy. These sickle cell therapies also bring us closer to an age of \u201c<a href=\"https:\/\/www.wired.com\/story\/the-age-of-crispr-medicine-is-here\/\">CRISPR medicine<\/a>\u201d in which new gene-editing tools could be used to fix a range of debilitating genetic diseases, including Duchenne muscular dystrophy and cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The cost of new gene-based sickle cell treatments isn\u2019t the only barrier to access. Coming up with new ways to treat the whole disease\u2014and person\u2014could make treatment more equitable. By Shobita Parthasarathy Last fall, to great fanfare, US regulators approved two gene therapies for sickle cell disease, and the European Union and UK soon followed. [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-191434","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/191434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=191434"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/191434\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=191434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=191434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=191434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}